Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Net Cash Flow (2016 - 2025)

CorMedix's Net Cash Flow history spans 13 years, with the latest figure at $96.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 1695.31% year-over-year to $96.3 million; the TTM value through Dec 2025 reached $105.1 million, up 3528.03%, while the annual FY2025 figure was $105.1 million, 3528.03% up from the prior year.
  • Net Cash Flow for Q4 2025 was $96.3 million at CorMedix, up from -$109.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $96.3 million in Q4 2025 and bottomed at -$109.9 million in Q3 2025.
  • The 5-year median for Net Cash Flow is -$3.1 million (2021), against an average of $5.0 million.
  • The largest YoY upside for Net Cash Flow was 1695.31% in 2025 against a maximum downside of 1729.66% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$13.0 million in 2021, then skyrocketed by 99.15% to -$111121.0 in 2022, then plummeted by 15990.82% to -$17.9 million in 2023, then surged by 130.01% to $5.4 million in 2024, then skyrocketed by 1695.31% to $96.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Net Cash Flow are $96.3 million (Q4 2025), -$109.9 million (Q3 2025), and $93.0 million (Q2 2025).